RFP: NCCN Pfizer Biosimilars (9.9.20)
The National Comprehensive Cancer Network® (NCCN®) is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity in support of biosimilars in oncology.
Organizations in the United States should submit initial Letters of Intent (LOIs) describing concepts that develop and validate enduring approaches to improve the safe, effective and efficient adoption of biosimilars in oncology.
LOIs that directly measure increases in biosimilar use or improve safety, value and efficiency in both academic and/or community-based oncology practices will be prioritized. The sustainability and broad applicability of the approach, and its potential to add value to cancer care delivery, will be key factors in evaluating fundable projects.
Application Deadline: To be considered for funding, LOIs must be submitted by 11:59 pm ET on Wednesday, September 9, 2020.
For more information: Please direct questions regarding this RFP to Nicole Kamienski at firstname.lastname@example.org with the subject line, “2020 Biosimilars Project.”